[Federal Register Volume 78, Number 162 (Wednesday, August 21, 2013)]
[Notices]
[Page 51747]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-20285]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application; 
NORAMCO, Inc.

    Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this 
is notice that on June 27, 2013, Noramco, Inc., 1440 Olympic Drive, 
Athens, Georgia 30601, made application by renewal to the Drug 
Enforcement Administration (DEA) for registration as an importer of the 
basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Phenylacetone (8501).......................  II
Thebaine (9333)............................  II
Poppy Straw Concentrate (9670).............  II
Tapentadol (9780)..........................  II
------------------------------------------------------------------------

    The company plans to import Thebaine (9333) analytical standards 
for distribution to its customers. The company plans to import an 
intermediate form of Tapentadol (9780) to bulk manufacture Tapentadol 
for distribution to its customers. The company plans to import the 
Phenylacetone (8501) in bulk for the manufacture of a controlled 
substance.
    Comments and requests for hearings on applications to import 
narcotic raw material are not appropriate. 72 FR 3417 (2007).
    In reference to the non-narcotic raw material, any bulk 
manufacturer who is presently, or is applying to be, registered with 
DEA to manufacture such basic classes of controlled substances listed 
in schedules I or II, which fall under the authority of section 
1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the 
circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than September 20, 2013.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants 
for registration to import a basic class of any controlled substances 
in schedule I or II are, and will continue to be, required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: August 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-20285 Filed 8-20-13; 8:45 am]
BILLING CODE 4410-09-P